GVK Biosciences in a drug repositioning collaboration with USFDA

GVK has licensed its proprietary databases to USFDA as part of the collaboration.

 

New Delhi, June 20, 2013: GVK Biosciences recently announced that the company has licensed its proprietary databases to USFDA as part of the collaboration in drug repositioning to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases.

 

As per the agreement, the company has licensed its SAR, PK and Toxicity Database (GOSTAR) to the US Food and Drug Administration (USFDA), the company said in a statement.

 

"The material transfer agreement forms the basis of collaboration in drug repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases," the company added.

 

It may be noted here that the company is looking at continuing working and collaborating with the USFDA with a view to further enhance the utility of the product.

 

The company also said that it has developed a proprietary 'Drug Repurposing Platform' with eight different approaches to address the drug repurposing challenge.

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...